AtLaS was a single-arm pilot study that demonstrated promising efficacy and safety of treatment simplification to a dual regimen with atazanavir/ritonavir + lamivudine in virologically suppressed HIV-positive patients. Here, we report data from the 144 week follow-up.
Mondi, A., Fabbiani, M., Ciccarelli, N., Colafigli, M., D'avino, A., Borghetti, A., Gagliardini, R., Cauda, R., De Luca, A., Di Giambenedetto, S., Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study, <<JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY>>, 2015; 70 (6): 1843-1849. [doi:10.1093/jac/dkv037] [http://hdl.handle.net/10807/68424]
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study
Mondi, Annalisa;Fabbiani, Massimiliano;Ciccarelli, Nicoletta;Colafigli, Manuela;D'Avino, Alessandro;Borghetti, Alberto;Gagliardini, Roberta;Cauda, Roberto;De Luca, Andrea;Di Giambenedetto, Simona
2015
Abstract
AtLaS was a single-arm pilot study that demonstrated promising efficacy and safety of treatment simplification to a dual regimen with atazanavir/ritonavir + lamivudine in virologically suppressed HIV-positive patients. Here, we report data from the 144 week follow-up.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
